Active Ingredient: Interferon, alfa-2b
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
5,000,000 - 10,000,000 [iU]
From 5,000,000 To 10,000,000 [iU] once every 2 day(s)
The recommended dose is in the range 5 to 10 million IU administered subcutaneously three times a week (every other day) for a period of 4 to 6 months.
The administered dose should be reduced by 50% in case of occurrence of haematological disorders (white blood cells <1,500/mm³, granulocytes <1,000/mm³, thrombocytes <100,000/mm³). Treatment should be discontinued in case of severe leukopaenia (<1,200/mm³), severe neutropaenia (<750/mm³) or severe thrombocytopaenia (<70,000/mm³).
For all patients, if no improvement on serum HBV-DNA is observed after 3 to 4 months of treatment (at the maximum tolerated dose), discontinue interferon alpha-2b therapy.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.